Elutia plans NXT-41x FDA submission this quarter after rabbit study results
Elutia said a GLP rabbit study of its drug-coated surgical matrix hit its performance goals, supporting a fourth-quarter 2026 FDA filing, while it reported $26 million in new non-dilutive funding.
Elutia Inc. reported third quarter 2026 results on November 5, 2026, and said it intends to submit NXT-41x, its leading drug delivery program, to the FDA in the fourth quarter of 2026, following positive results from a key performance study supporting the submission.1 Separately, the FDA review of NXT-41, the biologic surgical matrix without drug, remains on track, with a clearance decision anticipated this quarter.1
On the study itself, NXT-41x is a biologic matrix with an antibiotic coating on one side only, and in the GLP rabbit infection study the bacterial challenge was applied directly to the uncoated side as a worst-case test.1 The company said the product met its predetermined performance endpoints, achieving complete eradication of an 8-log MRSA and a 6-log E. coli challenge, with no viable bacteria recovered from either the matrix or the surrounding tissue.1 By comparison, every animal implanted with a matrix lacking antibiotics developed heavy colonization by the same pathogens.1
On financing, Elutia said it added $26 million in 51 days without an equity offering, and believes it has sufficient funding through NXT-41x clearance and launch.1 Sources of that funding included the August 17 closing of the SimpliDerm sale to Cellution Biologics Inc. for $8 million at closing, with up to $3 million more in contingent technology transfer and commercial milestone payments over 18 months,1 plus an August 11 $15 million loan facility with Avenue Capital Group, of which $10 million was funded at closing and $5 million more becomes available after NXT-41x FDA clearance.1
The company's updated timeline lists NXT-41 FDA clearance decision and NXT-41x FDA submission both expected in the fourth quarter of 2026, NXT-41x FDA clearance decision expected in the first half of 2027, a commercial soft launch in the second half of 2027, and full commercial launch in 2028.1 Cash and equivalents stood at $29.1 million as of September 30, 2026, not including the $8 million Boston Scientific holdback received October 1, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.